FLT3 tyrosine kinase inhibitors - PubMed (original) (raw)

Review

FLT3 tyrosine kinase inhibitors

Mark Levis et al. Int J Hematol. 2005 Aug.

Abstract

The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome. Efforts to target this mutation and improve out-comes in this subgroup of AML patients have led to the investigation of several novel small-molecule FLT3 tyrosine kinase inhibitors. These compounds derive from a wide variety of chemical classes and differ significantly, both in their potency and in their selectivity. In this review, we discuss the results of preclinical, clinical, and correlative laboratory studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the laboratory and the clinic.

PubMed Disclaimer

Similar articles

• FLT3 inhibitors in acute myeloid leukemia.
  el-Shami K, Stone RM, Smith BD. el-Shami K, et al. Expert Rev Hematol. 2008 Dec;1(2):153-60. doi: 10.1586/17474086.1.2.153. Expert Rev Hematol. 2008. PMID: 21082920 Review.
• T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.
  Alachkar H, Mutonga M, Malnassy G, Park JH, Fulton N, Woods A, Meng L, Kline J, Raca G, Odenike O, Takamatsu N, Miyamoto T, Matsuo Y, Stock W, Nakamura Y. Alachkar H, et al. Oncotarget. 2015 Oct 20;6(32):33410-25. doi: 10.18632/oncotarget.5418. Oncotarget. 2015. PMID: 26450903 Free PMC article.
• Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
  Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X, Estrov Z, Quintás-Cardama A, Small D, Cortes J, Andreeff M. Zhang W, et al. J Natl Cancer Inst. 2008 Feb 6;100(3):184-98. doi: 10.1093/jnci/djm328. Epub 2008 Jan 29. J Natl Cancer Inst. 2008. PMID: 18230792 Clinical Trial.
• Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
  Kayser S, Levis MJ, Schlenk RF. Kayser S, et al. Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10. Expert Rev Clin Pharmacol. 2017. PMID: 28960095 Review.
• The clinical development of FLT3 inhibitors in acute myeloid leukemia.
  Knapper S. Knapper S. Expert Opin Investig Drugs. 2011 Oct;20(10):1377-95. doi: 10.1517/13543784.2011.611802. Epub 2011 Sep 6. Expert Opin Investig Drugs. 2011. PMID: 21895538 Review.

Cited by

• FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
  Zhang Y, Hsu CP, Lu JF, Kuchimanchi M, Sun YN, Ma J, Xu G, Zhang Y, Xu Y, Weidner M, Huard J, D'Argenio DZ. Zhang Y, et al. J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):675-91. doi: 10.1007/s10928-014-9393-x. Epub 2014 Oct 19. J Pharmacokinet Pharmacodyn. 2014. PMID: 25326874 Free PMC article.
• FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.
  Acharya B, Saha D, Armstrong D, Lakkaniga NR, Frett B. Acharya B, et al. RSC Med Chem. 2022 May 23;13(7):798-816. doi: 10.1039/d2md00067a. eCollection 2022 Jul 20. RSC Med Chem. 2022. PMID: 35923716 Free PMC article. Review.
• Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.
  Brown P, Smith FO. Brown P, et al. Paediatr Drugs. 2008;10(2):85-92. doi: 10.2165/00148581-200810020-00003. Paediatr Drugs. 2008. PMID: 18345718 Review.
• Bench to bedside targeting of FLT3 in acute leukemia.
  Pratz KW, Levis MJ. Pratz KW, et al. Curr Drug Targets. 2010 Jul;11(7):781-9. doi: 10.2174/138945010791320782. Curr Drug Targets. 2010. PMID: 20370649 Free PMC article. Review.
• Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication.
  Abe A, Kiyoi H, Ninomiya M, Yamazaki T, Murase T, Ozeki K, Suzuki M, Hayakawa F, Katsumi A, Emi N, Naoe T. Abe A, et al. Int J Hematol. 2006 Nov;84(4):328-36. doi: 10.1532/IJH97.06056. Int J Hematol. 2006. PMID: 17118759

References

1. 1. Blood. 2003 Feb 15;101(4):1494-504 - PubMed
2. 1. Blood. 2002 Oct 1;100(7):2387-92 - PubMed
3. 1. Leukemia. 2002 Oct;16(10):2027-36 - PubMed
4. 1. Cancer Cell. 2002 Jun;1(5):433-43 - PubMed
5. 1. N Engl J Med. 1955 Nov 3;253(18):754-61 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal